NCT01764022: A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients |
|
|
| Completed | 3 | 225 | RoW | Trastuzumab, BCD-022, Herceptin, Paclitaxel, Taxacad | Biocad | Human Epithelial Receptor (HER)-2 Positive Breast Cancer | 03/15 | 12/17 | | |
